ReviewCureus2023

An Overview of Safety and Efficacy Between Hypoxia-Inducible Factor-Prolyl-Hydroxylase Inhibitors and Erythropoietin-Stimulating Agents in Treating Anemia in Chronic Kidney Disease Patients.

Shamsun Nahar Sonia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.